News Search Results
Aug 21, 2025, 08:00 ET ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment
streamline workflows, lower costs, improve outcomes, and elevate the patient experience," says Magnus Reibenspiess, Head of Strategic Business Unit Ophthalmology at ZEISS Medical Technology. "The AI decision support capabilities of ZEISS CIRRUS PathFinder help enable faster, more informed and actionable diagnostics
More news about: Carl Zeiss Meditec AG
Aug 21, 2025, 02:49 ET Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Aug 21, 2025, 02:41 ET Piramal Pharma Solutions and NewAmsterdam Pharma Invest in Dedicated Suite to Enhance Oral Solid Dosage Production Capabilities at Piramal's Sellersville, Pennsylvania Site
associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics
More news about: Piramal Pharma Solutions
Aug 20, 2025, 14:41 ET Parker Waichman LLP Files Lawsuit on behalf of Long Island Resident Alleging Vision Loss and Development of Irreversible Eye Condition, NAION, after taking Ozempic
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority
More news about: Parker Waichman LLP
Aug 18, 2025, 20:00 ET RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
clinical trial results of RC28-E for diabetic macular edema (DME) were presented as an oral report at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting. The study demonstrated that RC28-E significantly improved best-corrected visual acuity (BCVA) and reduced central subfield
More news about: RemeGen Co., Ltd
Aug 14, 2025, 08:36 ET Nanoscope Therapeutics Announces Publication of STARLIGHT Phase 2 Study Evaluating MCO-010 Gene-Agnostic Therapy in Patients with Stargardt Disease
Byron Lam, MD, Professor of Ophthalmology at Bascom Palmer Eye Institute, lead author and principal investigator of the STARLIGHT study. "I am thrilled to be part of the upcoming Phase
More news about: Nanoscope Therapeutics
Aug 13, 2025, 11:36 ET Parker Waichman LLP Files Lawsuit on behalf of Florida Woman Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications,
More news about: Parker Waichman LLP
Aug 12, 2025, 12:00 ET VivaVision Strengthens Scientific Advisory Board with a World-Renowned Expert in Ophthalmology
Scientific Advisory Board. Quan Dong Nguyen, MD, MSc, FAAO, FARVO, FASRS, is currently a professor of ophthalmology at the Byers Eye Institute, Stanford University School of Medicine; he is also a professor
More news about: VIVAVISION BIOTECH LTD
Aug 12, 2025, 11:09 ET Healthcare AI Market Explodes 38.5% Annually as Diagnostics Gain FDA Traction
clinical sites. Ainnova will collaborate directly with Fortrea, a globally recognized contract research organization specializing in ophthalmology studies, to recruit patients primarily from community clinics and primary care facilities. This approach captures real-world data that reflects
More news about: USA News Group
Aug 12, 2025, 09:10 ET Parker Waichman LLP Requests that all Ozempic/Wegovy NAION New Jersey State Court lawsuits be Consolidated
concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from
More news about: Parker Waichman LLP
Aug 12, 2025, 08:00 ET Avant Technologies and Ainnova Tech Announce Enhanced Patient Recruitment Strategy Ahead of FDA Clinical Trial
retinopathy. Ainnova will work directly with Fortrea, a globally recognized Contract Research Organization (CRO) renowned for its expertise in ophthalmology studies and medical device trials, following the guidance the Company received from its recent meeting with the U.S. Food and Drug Administration
More news about: Avant Technologies Inc.
Aug 07, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LACRIFILL® CANALICULAR GEL INCLUSION IN NEW DRY EYE WORKSHOP (DEWS) III MANAGEMENT AND THERAPY REPORT FROM THE TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) IN AMERICAN JOURNAL OF OPHTHALMOLOGY
be the subject of a poster presentation at the Women in Ophthalmology (WIO) Summer Symposium on August 7–10. The DEWS III report, which appears in the June 2025 issue of American Journal of Ophthalmology, cites two studies of Nordic Pharma's novel crosslinked
More news about: Nordic Pharma
Aug 07, 2025, 10:00 ET NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES LACRIFILL® CANALICULAR GEL INCLUSION IN NEW DRY EYE WORKSHOP (DEWS) III MANAGEMENT AND THERAPY REPORT FROM THE TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) IN AMERICAN JOURNAL OF OPHTHALMOLOGY
be the subject of a poster presentation at the Women in Ophthalmology (WIO) Summer Symposium on August 7–10. The DEWS III report, which appears in the June 2025 issue of American Journal of Ophthalmology, cites two studies of Nordic Pharma's novel crosslinked
More news about: Nordic Pharma
Aug 07, 2025, 10:00 ET NORDIC GROUP B.V. DURCH SEINE TOCHTERGESELLSCHAFT NORDIC PHARMA, INC. (U.S.), GIBT DIE AUFNAHME VON LACRIFILL® KANALIKULÄREM GEL IN DEN NEUEN BERICHT ÜBER MANAGEMENT UND THERAPIE DES TROCKENEN AUGES (DEWS) III DER GESELLSCHAFT FÜR TRÄNENFILM UND AUGENOBERFLÄCHE (TFOS) IM AMERICAN JOURNAL OF OPHTHALMOLOGY BEKANNT
Gel wird auch Gegenstand einer Posterpräsentation auf dem Women in Ophthalmology (WIO) Summer Symposium vom 7. bis 10. August sein. Der DEWS-III-Bericht, der in der Juni-Ausgabe 2025 des American Journal of Ophthalmology erscheint, zitiert in Abschnitt 6.2.4 "Newer Plug Designs and Other
More news about: Nordic Pharma
Aug 07, 2025, 10:00 ET NORDIC GROUP B.V. PAR L'INTERMÉDIAIRE DE SA FILIALE NORDIC PHARMA, INC. (U.S.), ANNONCE L'INCLUSION DU GEL CANALICULAIRE LACRIFILL® DANS LE NOUVEAU RAPPORT SUR LA GESTION ET LA THÉRAPIE DU DRY EYE WORKSHOP (DEWS) III DE LA TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) DANS L'AMERICAN JOURNAL OF OPHTHALMOLOGY
également l'objet d'une présentation par affiches lors du Women in Ophthalmology (WIO) Summer Symposium qui se tiendra du 7 au 10 août. Le rapport DEWS III, publié dans le numéro de juin 2025 de American Journal of Ophthalmology, cite deux études sur le nouveau produit de comblement canaliculaire
More news about: Nordic Pharma
Aug 07, 2025, 10:00 ET INCLUSIÓN DEL GEL CANALICULAR LACRIFILL® EN EL NUEVO INFORME DEL TALLER DE OJO SECO (DEWS) III
NUEVO INFORME DE MANEJO Y TERAPIA DEL TALLER DE OJO SECO (DEWS) III DE LA TEAR FILM AND OCULAR SURFACE SOCIETY (TFOS) EN AMERICAN JOURNAL OF OPHTHALMOLOGY BERWYN, Pa., 7 de agosto de 2025
More news about: Nordic Pharma
Aug 07, 2025, 10:00 ET Mayo Clinic in Florida designated as Cavernous Malformation Clinical Center
addition to neurology and neurosurgery, the CCM Clinical Center team includes experts in epileptology, genetics, neuroradiology, dermatology, and neuro-ophthalmology. Patients can call 904-953-0856 to schedule a consultation with the CCM Clinical Center at Mayo Clinic in Florida.
More news about: Alliance to Cure Cavernous Malformation
Aug 07, 2025, 08:52 ET Eyesafe Report Finds the Average Person Will Spend 21 Years on Screens
a world-class team of eye doctors, engineers, and scientists with expertise in electronics, display materials, light management, optometry, and ophthalmology. The Eyesafe brand is trusted by millions of consumers and integrated into digital devices from Dell, HP, Lenovo, LG, ZAGG, and more. Recognized
More news about: Eyesafe
Aug 07, 2025, 07:00 ET REGENXBIO Announces Pivotal Program for Surabgene Lomparvovec in Diabetic Retinopathy
2010;376(9735):124–36.3 Lundeen EA, Burke-Conte Z, Rein DB, Wittenborn JS, Saaddine J, Lee AY, Flaxman AD. Prevalence of Diabetic Retinopathy in the US in 2021. JAMA Ophthalmology. 2023;141(8):747-754.4 Berrocal MD, Alexandra Acabá. Current Management of Diabetic Retinopathy, 2018
More news about: REGENXBIO Inc.
Aug 06, 2025, 14:45 ET OCLI Vision Welcomes Ophthalmologist Dr. Maryam Ige to Queens Locations at the Fishman Center for Total Eye Care
Dr. Ige brings a wealth of clinical and academic experience to OCLI Vision. She recently completed her ophthalmology residency at Northwestern University, where she served as Chief Resident. Throughout her training, Dr. Ige has been
More news about: OCLI Vision
Aug 06, 2025, 06:45 ET Mallinckrodt Names Christiana Stamoulis as President and Chief Financial Officer
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Aug 06, 2025, 06:30 ET Mallinckrodt plc Reports Financial Results for Second Quarter 2025 and Provides Guidance
diseases in areas including endocrinology, gastroenterology, hepatology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology, and urology. Our Par Health business includes generic drugs, sterile injectables, and active pharmaceutical ingredients.
More news about: Mallinckrodt plc
Aug 05, 2025, 11:00 ET Four BASIS Charter Schools Students Earn Coveted Spots in Accelerated Medical Program at University of Arizona College of Medicine - Tucson
communication and critical thinking skills that set him apart in the competitive medical school admissions process. He hopes to pursue a career in ophthalmology, where he can directly improve patients' lives through surgical care to restore vision. "Medicine is about helping people, but it's also
More news about: BASIS Charter Schools
Aug 05, 2025, 10:55 ET Biomaterials Market to Grow at a CAGR of 15.5% from 2025 to 2032 | SkyQuest Technology Consulting
biomaterials, ceramic biomaterials, natural biomaterials. Based on the application, the market is segmented into neurology, cardiology, orthopedics, ophthalmology, wound care, dental, plastic surgery, and other applications. By type, metallic biomaterials are dominated by titanium
More news about: SkyQuest Technology
Aug 05, 2025, 08:30 ET InMode to Participate in Upcoming Investor Conferences
technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode, please visit www.inmodemd.com. Forward-Looking
More news about: InMode Ltd.